Your personalized plan will outline the recommended dosing to maximize benefits
This peptide has been shown to promote the healing of joint tissues, reduce pain, and improve joint function
In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmaceutical companies, and there is insufficient evidence regarding potential harm to humans
BPC-157 Tissue-Repair & Recovery-Focused Pathways BPC-157 (Body Protection Compound-157) is commonly researched for its interaction with: Tissue-repair and recovery-focused signaling Barrier-function and gastrointestinal-related pathways Cellular-repair and physiological-resilience mechanisms Angiogenesis-related signaling pathways Recovery-focused regenerative research Research involving BPC-157 commonly investigates its potential interaction with soft-tissue and connective-tissue pathways, circulation-related mechanisms, and recovery-focused physiological signaling
A loading phase of 1mg three times weekly for two weeks, then maintenance of 1mg every two to three months, adjusted for the cause and any neurological involvement
